Key result
Elevated cardiometabolic index is linked to ~66% higher odds of progression to advanced CKM syndrome.
Why the study?
The longitudinal association between cardiometabolic index and progression of cardiovascular-kidney-metabolic syndrome stages was not previously evaluated in a middle-aged and elderly population.
Does an elevated cardiometabolic index predict stage progression in cardiovascular-kidney-metabolic syndrome in a middle-aged and elderly Chinese population?
Cohort (n=4,080)
Yes
Does an elevated cardiometabolic index predict stage progression in cardiovascular-kidney-metabolic syndrome in a middle-aged and elderly Chinese population?
Odds Ratio: 1.66 (95% CI 1.32–2.11)
Elevated cardiometabolic index is significantly associated with longitudinal progression of cardiovascular-kidney-metabolic syndrome stages, suggesting its utility as a simple risk assessment tool.
BACKGROUND: The emerging concept of cardiovascular-kidney-metabolic syndrome (CKM) highlights the pathophysiological interconnection between cardiorenal and metabolic disorders. This study investigates the longitudinal association between the cardiometabolic index (CMI) and CKM stage progression. METHODS AND RESULTS: This study utilized data from the China Health and Retirement Longitudinal Study. The baseline CMI was computed utilizing the triglycerides-to-high-density lipoprotein cholesterol ratio multiplied by the waist-to-height ratio. CKM is defined and categorized into five stages (0-4) based on metabolic, cardiovascular, and renal disorders. We evaluated the impact of CMI on the CKM stage progression from Wave 1(2011) to Wave 3(2015). Multivariable logistic regression and restricted cubic spline (RCS) models were constructed to illustrate the relationship between CMI and CKM stage progression. A total of 4080 patients were included. The rate of CKM progression to advanced stages significantly increased with higher CMI quartiles. When entered into the multivariable logistic regressions as a continuous variable, elevated CMI was a remarkable predictor for progression to CKM stages 2-4 among participants at baseline CKM stages 0-1 [OR(95%CI) 1.66 (1.32-2.11)], progression to CKM stages 3-4 among those at baseline CKM stages 0-2 [OR(95%CI) 1.14 (1.03-1.26)], and progression to CKM stage 4 among those at baseline CKM stages 0-3 [OR(95%CI) 1.13 (1.00-1.28)], after adjustment for potential confounders. This association persisted when CMI was modeled as a categorical variable. RCS analysis demonstrated significant positive associations between elevated CMI levels and an increased risk of progression to advanced CKM stages (all P < 0.05). CONCLUSION: Elevated CMI is significantly associated with CKM stage progression over time. CMI could act as a simple, useful tool for the risk assessment of CKM.
No takes yet. Share an insight, caveat, or question.
Lyu et al. (2026) conducted a cohort in Cardiovascular-kidney-metabolic syndrome (CKM) (n=4,080). Elevated cardiometabolic index (CMI) vs. Lower cardiometabolic index (CMI) was evaluated on Progression to CKM stages 2-4 among participants at baseline CKM stages 0-1 (OR 1.66, 95% CI 1.32-2.11). Elevated cardiometabolic index significantly predicted progression to advanced cardiovascular-kidney-metabolic syndrome stages, with an OR of 1.66 for progression to stages 2-4 among participants at baseline stages 0-1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: